Spur Therapeutics

CompanyUnited Kingdom

Spur Therapeutics develops one asset, in phase 3 (Avigbagene parvec in Gaucher disease). Mostly gene therapy acting on autophagy and GBA1; based in the United Kingdom.

1
Asset
Furthest stage: Phase 3; 0
Trials: 0
Signals

Pipeline

1

Avigbagene parvec
AAV gene therapy encoding engineered glucocerebrosidase
Phase 3, Gene therapy, Autophagy, GBA1, Gaucher disease

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms2
Similar companies6